Profile data is unavailable for this security.
About the company
Mirum Pharmaceuticals, Inc. is a rare disease company with a global footprint of approved products and a pipeline of investigational medicines. Its commercial portfolio includes LIVMARLI (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM (cholic acid) for bile-acid synthesis disorders, and CTEXLI (chenodiol) for cerebrotendinous xanthomatosis (CTX). Its clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV), and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS). Livmarli is an orally administered, minimally absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with ALGS in the United States and other countries.
- Revenue in USD (TTM)521.31m
- Net income in USD-23.36m
- Incorporated2018
- Employees369.00
- LocationMirum Pharmaceuticals Inc989 EAST HILLSDALE BOULEVARD, SUITE 300FOSTER CITY 94404United StatesUSA
- Phone+1 (650) 667-4085
- Fax+1 (302) 269-3855
- Websitehttps://mirumpharma.com/
More ▼
Mergers & acquisitions
| Acquired company | MIRM:NMQ since announced | Transaction value |
|---|---|---|
| Bluejay Therapeutics Inc | 28.21% | 820.00m |
Data delayed at least 15 minutes, as of Mar 03 2026 21:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Catalyst Pharmaceuticals Inc | 588.99m | 214.33m | 2.92bn | 182.00 | 14.20 | 3.07 | 11.58 | 4.96 | 1.68 | 1.68 | 4.63 | 7.79 | 0.6024 | 3.08 | 6.14 | 3,236,203.00 | 21.92 | 22.15 | 25.40 | 25.81 | 85.19 | 85.59 | 36.39 | 31.20 | 5.82 | -- | 0.00 | 0.00 | 19.78 | 37.68 | 30.78 | 23.37 | 38.45 | -- |
| Arcutis Biotherapeutics Inc | 376.07m | -16.14m | 2.93bn | 354.00 | -- | 15.36 | -- | 7.78 | -0.1325 | -0.1325 | 2.93 | 1.54 | 0.962 | 1.97 | 3.43 | 1,062,350.00 | -4.13 | -48.93 | -5.65 | -57.14 | 90.24 | -- | -4.29 | -147.21 | 2.99 | -3.84 | 0.3651 | -- | 91.34 | -- | 88.47 | -- | 101.59 | -- |
| Supernus Pharmaceuticals Inc | 718.95m | -38.55m | 3.14bn | 674.00 | -- | 2.95 | 59.14 | 4.37 | -0.6839 | -0.6839 | 12.70 | 18.48 | 0.5098 | 1.09 | 4.36 | -- | -2.73 | 2.01 | -3.52 | 2.67 | 89.63 | 87.96 | -5.36 | 4.66 | 1.66 | -- | -- | -- | 8.63 | 6.68 | -152.19 | -- | -- | -- |
| Tarsus Pharmaceuticals Inc | 451.36m | -66.42m | 3.26bn | 370.00 | -- | 9.49 | -- | 7.22 | -1.61 | -1.61 | 10.81 | 8.07 | 0.9612 | 8.78 | 6.85 | 1,219,892.00 | -14.14 | -27.80 | -18.38 | -32.78 | 93.20 | 93.45 | -14.72 | -53.60 | 3.82 | -- | 0.1742 | -- | 146.71 | -- | 42.52 | -- | 84.92 | -- |
| Prestige Consumer Healthcare Inc | 1.10bn | 186.50m | 3.26bn | 600.00 | 18.25 | 1.78 | 15.07 | 2.96 | 3.78 | 3.78 | 22.38 | 38.66 | 0.3234 | 3.07 | 6.17 | 1,839,343.00 | 5.47 | 4.13 | 5.67 | 4.30 | 56.12 | 56.31 | 16.90 | 13.13 | 1.93 | 8.28 | 0.3657 | 0.00 | 1.10 | 3.39 | 2.52 | 8.57 | -13.84 | -- |
| Kiniksa Pharmaceuticals Internationl PLC | 677.56m | 59.01m | 3.47bn | 366.00 | 60.92 | 6.10 | 57.34 | 5.12 | 0.7448 | 0.7448 | 8.58 | 7.44 | 1.01 | 1.91 | 23.64 | 1,851,268.00 | 8.78 | 2.35 | 10.69 | 2.75 | 88.54 | 87.48 | 8.71 | 3.40 | 3.39 | -- | 0.00 | 0.00 | 60.09 | -- | 236.61 | -- | 40.84 | -- |
| Corcept Therapeutics Inc | 761.41m | 99.65m | 3.75bn | 730.00 | 42.49 | 5.77 | 37.23 | 4.93 | 0.8303 | 0.8303 | 6.35 | 6.11 | 0.908 | 1.03 | 13.39 | 1,043,023.00 | 11.88 | 17.68 | 14.54 | 20.76 | 98.30 | 98.47 | 13.09 | 20.88 | 2.85 | -- | 0.00 | 0.00 | 12.79 | 16.56 | -29.43 | -1.23 | -29.80 | -- |
| Indivior Pharmaceuticals, Inc | 1.18bn | 122.00m | 3.86bn | 1.03k | 32.18 | -- | 26.09 | 3.27 | 0.9592 | 0.9592 | 9.20 | -1.66 | 0.8194 | 1.03 | 4.63 | 1,145,631.00 | 8.68 | -1.36 | 26.23 | -2.98 | 85.51 | 84.87 | 10.59 | -2.47 | 0.7938 | 9.33 | 2.80 | -- | 8.69 | 8.64 | 101.55 | -56.87 | 34.66 | -- |
| ADMA Biologics Inc | 510.17m | 146.93m | 3.90bn | 647.00 | 27.32 | 8.16 | 25.16 | 7.65 | 0.5996 | 0.5996 | 2.08 | 2.01 | 0.9168 | 1.15 | 4.90 | 788,520.90 | 26.40 | 9.62 | 29.75 | 10.91 | 57.39 | 44.75 | 28.80 | 12.51 | 3.74 | 37.09 | 0.1313 | 0.00 | 19.63 | 64.60 | -25.67 | -- | 12.46 | -- |
| Ligand Pharmaceuticals Inc | 251.23m | 48.58m | 4.07bn | 68.00 | 98.29 | 4.23 | 49.19 | 16.21 | 2.08 | 2.08 | 12.77 | 48.34 | 0.2066 | 1.01 | 5.47 | 3,694,603.00 | 4.00 | 1.82 | 4.09 | 1.92 | 94.27 | 82.57 | 19.34 | 10.30 | 24.30 | -- | 0.3192 | 0.00 | 27.28 | 6.80 | -107.49 | -- | -6.53 | -- |
| Amneal Pharmaceuticals Inc | 3.02bn | 72.06m | 4.19bn | 8.50k | 59.49 | -- | 11.91 | 1.39 | 0.2237 | 0.2237 | 9.29 | -0.225 | 0.8409 | 3.13 | 3.61 | 355,148.30 | 3.56 | -1.24 | 5.09 | -1.61 | 36.88 | 36.59 | 4.24 | -1.83 | 1.48 | 1.70 | 0.9977 | -- | 8.05 | 8.66 | 161.65 | -- | 11.56 | -- |
| TG Therapeutics Inc | 616.29m | 447.18m | 4.61bn | 399.00 | 10.40 | 6.92 | 10.31 | 7.48 | 2.78 | 2.78 | 3.82 | 4.17 | 0.7511 | 0.8534 | 2.83 | 1,544,579.00 | 54.50 | -3.81 | 64.04 | -4.57 | 83.66 | 87.01 | 72.56 | -7.46 | 3.29 | 4.61 | 0.2749 | -- | 87.32 | 426.73 | 1,812.41 | -- | -9.73 | -- |
| Mirum Pharmaceuticals Inc | 521.31m | -23.36m | 5.30bn | 369.00 | -- | 14.48 | 6,013.61 | 10.16 | -0.4783 | -0.4783 | 10.07 | 6.06 | 0.6889 | 4.24 | 5.17 | 1,412,770.00 | -3.09 | -19.72 | -3.96 | -23.84 | 80.77 | 78.68 | -4.48 | -43.34 | 2.55 | -13.32 | 0.4961 | -- | 54.74 | -- | 73.43 | -- | 33.50 | -- |
| PTC Therapeutics, Inc. | 1.73bn | 682.64m | 5.33bn | 991.00 | 8.29 | -- | 7.39 | 3.08 | 7.77 | 7.77 | 20.73 | -2.52 | 0.7518 | 0.9143 | 10.18 | 1,746,372.00 | 29.66 | -14.19 | 44.70 | -19.65 | 97.28 | 94.76 | 39.44 | -29.50 | 2.27 | 5.24 | 1.09 | -- | 114.51 | 35.37 | 287.90 | -- | -13.07 | -- |
| Rhythm Pharmaceuticals Inc | 189.76m | -201.92m | 6.12bn | 414.00 | -- | 43.28 | -- | 32.23 | -3.11 | -3.11 | 2.92 | 4.02 | 0.435 | 0.8762 | 8.51 | 458,350.30 | -45.05 | -50.41 | -60.38 | -61.35 | 89.73 | 89.41 | -103.57 | -210.46 | 4.16 | -36.30 | 0.286 | -- | 45.83 | -- | 23.68 | -- | 34.81 | -- |
Data as of Mar 03 2026. Currency figures normalised to Mirum Pharmaceuticals Inc's reporting currency: US Dollar USD
42.25%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Janus Henderson Investors US LLCas of 31 Dec 2025 | 5.93m | 11.47% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 3.13m | 6.05% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 2.24m | 4.34% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 2.14m | 4.15% |
| Eventide Asset Management LLCas of 31 Dec 2025 | 2.09m | 4.05% |
| BVF Partners LPas of 31 Dec 2025 | 1.50m | 2.89% |
| T. Rowe Price Associates, Inc. (IM)as of 31 Dec 2025 | 1.38m | 2.66% |
| Tang Capital Management LLCas of 31 Dec 2025 | 1.24m | 2.39% |
| Wellington Management Co. LLPas of 31 Dec 2025 | 1.13m | 2.19% |
| Geode Capital Management LLCas of 31 Dec 2025 | 1.06m | 2.06% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
